Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Non-Current Deffered Revenue: 2010-2024

Historic Non-Current Deffered Revenue for Ligand Pharmaceuticals (LGND) over the last 10 years, with Dec 2024 value amounting to $2.2 million.

  • Ligand Pharmaceuticals' Non-Current Deffered Revenue rose 55.54% to $2.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.2 million, marking a year-over-year increase of 55.54%. This contributed to the annual value of $2.2 million for FY2024, which is 55.54% up from last year.
  • As of FY2024, Ligand Pharmaceuticals' Non-Current Deffered Revenue stood at $2.2 million, which was up 55.54% from $1.4 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Non-Current Deffered Revenue peaked at $9.3 million during FY2021, and registered a low of $44,000 during FY2022.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $1.4 million (2023), whereas its average is $1.2 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first tumbled by 99.53% in 2022, then spiked by 3,181.82% in 2023.
  • Yearly analysis of 4 years shows Ligand Pharmaceuticals' Non-Current Deffered Revenue stood at $9.3 million in 2021, then tumbled by 99.53% to $44,000 in 2022, then surged by 3,181.82% to $1.4 million in 2023, then surged by 55.54% to $2.2 million in 2024.